Open Label Study to Evaluate the Safety of Copaxone(R) and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone(R) .

Trial Profile

Open Label Study to Evaluate the Safety of Copaxone(R) and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone(R) .

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Teva Neuroscience; Teva Pharmaceutical Industries
  • Most Recent Events

    • 06 Dec 2017 Planned End Date changed from 1 Sep 2019 to 28 Jun 2019.
    • 06 Dec 2017 Planned primary completion date changed from 1 Aug 2019 to 28 Jun 2019.
    • 14 Jun 2016 Time frame of primary end points has been changed from 17 years to 26 years.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top